Journal
ALZHEIMERS & DEMENTIA
Volume 16, Issue 2, Pages 283-291Publisher
WILEY
DOI: 10.1016/j.jalz.2019.08.189
Keywords
Alzheimer's disease; Amyloid beta (A beta); Apolipoprotein E (APOE); Vascular dementia; Blood plasma; Risk stratification
Categories
Funding
- Baden-Wurttemberg Ministry of Science
- Federal Ministry of Education and Research
- German Federal Ministry of Family
- University of Heidelberg
- Klaus Tschira Foundation
Ask authors/readers for more resources
Introduction: Alzheimer's disease (AD) has a long prodromal stage and identifying high-risk individuals is critical. We aimed to investigate the ability of A beta misfolding in blood plasma, APOE4 status, and dementia risk factors to predict diagnosis of AD. Methods: Within a community-based cohort, A beta misfolding in plasma measured by immuno-infrared sensor and APOE genotypewere determined at baseline in 770 participants followed over 14 years. Associations between A beta misfolding, APOE4, and other predictors with clinical AD, vascular dementia, and mixed dementia diagnoses were assessed. Results: A beta misfolding was associated with a 23-fold increased odds of clinical AD diagnosis within 14 years. No association was observed with vascular dementia/mixed dementia diagnoses. APOE4-positive participants had a 2.4-fold increased odds of clinical AD diagnosis within 14 years. Discussion: A beta misfolding in blood plasma was a strong, specific risk prediction marker for clinical AD evenmany years before diagnosis in a community-based setting.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available